Biomarkers of DNA repair and related pathways: Significance in non-small cell lung cancer

Current Opinion in Oncology

Volumn 23, Issue 2, 2011, Pages 150-157

  Rothschild, Sacha I ^a   Gautschi, Oliver ^a   Lara, Primo N ^b   MacK, Philip C ^b   Gandara, David R ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarker; chemotherapy; gene expression; lung cancer; personalized medicine

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; GENOMIC DNA; IFOSFAMIDE; IRINOTECAN; MOLECULAR MARKER; NAVELBINE; PEMETREXED; PLATINUM DERIVATIVE; RECEPTOR ASSOCIATED PROTEIN 80; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE MESSENGER 1; THYMIDYLATE SYNTHASE; UBIQUITIN INTERACTING MOTIF CONTAINING 1; UNCLASSIFIED DRUG; VINBLASTINE;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME SUBUNIT; EXCISION REPAIR; GENE EXPRESSION; GENOTYPE; HISTOLOGY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952006300     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328341ee38     Document Type: Article

References (77)

1. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with nonsmall cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26:173-182. (Pubitemid 38759943)
2. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA nonsmall- cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719-727. (Pubitemid 44283661)
3. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected nonsmall-cell lung cancer. N Engl J Med 2005; 352:2589-2597. (Pubitemid 41007845)
4. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer. N Engl J Med 2004; 350:351-360. (Pubitemid 38101630)
5. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA nonsmall-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453-1461. (Pubitemid 37279330)
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002; 346:92-98. (Pubitemid 34438899)
7. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63:12-31. (Pubitemid 46810280)
8. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anticancer chemotherapy. Cancer Treat Rev 1998; 24:331-344. (Pubitemid 28537769)
9. Tsai CM, Chang KT, Li L, et al. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in nonsmall cell lung cancer cells. Jpn J Cancer Res 2000; 91:213-222. (Pubitemid 30130752)
10. Hansson J, Wood RD. Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II). Nucleic Acids Res 1989; 17:8073-8091. (Pubitemid 19267164)
11. Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in nonsmall cell lung cancer. Int J Cancer 2007; 121:895-900. (Pubitemid 47106222)
12. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004; 14:959-970.
13. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with nonsmall cell lung cancer. Chest 2005; 127:978-983. (Pubitemid 40775532)
14. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in nonsmall cell lung cancer. Clin Cancer Res 2002; 8:2286-2291. (Pubitemid 34753602)
15. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced nonsmall-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009; 64:98-104.
16. Fujii T, Toyooka S, Ichimura K, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in nonsmall-cell lung cancer. Lung Cancer 2008; 59:377-384. (Pubitemid 351335101)
17. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmallcell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-991. (Pubitemid 44343542)
18. Bepler J. ERCC1, RRM1, and BRCA1 gene expression and outcome prediction; oral presentation, ITOCD Dresden, Germany, 2010.
19. Boni C, Baldini E, Boni L, et al. Triplets versus doublets with or without cisplatin in the first-line treatment of stage IIIB-IV nonsmall cell lung cancer (NSCLC) patients: preliminary results of a multicenter randomized factorial study. J Thorac Oncol 2007; 2:S318.
20. Tiseo M, Bordi P, Bortesi B, et al. ERCC 1/BRCA1 protein expressions and ERCC1/XPD/XRCC1-3 gene polymorphisms as predictor factors of outcome in stage IIIB-IV nonsmall cell lung cancer (NSCLC) patients treated in first-line chemotherapy with or without cisplatin. J Thorac Oncol 2009; 4:D7.5.
21. Chen S, Zhang J, Wang R, et al. The platinum-based treatments for advanced nonsmall cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010; 70:63-70.
22. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in nonsmall-cell lung cancer. J Clin Oncol 2007; 25:2747-2754. (Pubitemid 47123183)
23. Booton R, Ward T, Ashcroft L, et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced nonsmall cell lung cancer. J Thorac Oncol 2007; 2:902-906. (Pubitemid 47511592)
24. Besse B, Massard C, Haddad V, et al. ERCC1 influence on the incidence of brain metastases in patients with nonsquamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Ann Oncol 2010. [Epub ahead of print]
25. Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94:703-708. (Pubitemid 24251002)
26. Smith S, Su D, Rigault de la Longrais IA, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007; 25:5172-5179. (Pubitemid 350232247)
27. Steffensen KD, Waldstrom M, Jakobsen A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19:820-825.
28. Wei J, Zou Z, Qian X, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008; 98:1398-1402. (Pubitemid 351543582)
29. Fareed KR, Al-Attar A, Soomro IN, et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastrooesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 2010; 102:1600-1607.
30. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-316. (Pubitemid 28041614)
31. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-4304. (Pubitemid 33096777)
32. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in nonsmall-cell lung cancer. J Clin Oncol 2006; 24:4731-4737. (Pubitemid 46646245)
33. Grindey GB, Hertel LW, Plunkett W. Cytotoxicity and antitumor activity of 20,20-difluorodeoxycytidine (Gemcitabine). Cancer Invest 1990; 8:313.
34. Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 20,20-difluorodeoxycytidine. Mol Pharmacol,1990: 138, 567-572. (Pubitemid 20356209)
35. Pereira S, Fernandes PA, Ramos MJ. Theoretical study of ribonucleotide reductase mechanism-based inhibition by 20-azido-20-deoxyribonucleoside 50-diphosphates. J Comput Chem 2004; 25:227-237.
36. Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 2003; 22:2135-2142. (Pubitemid 36539563)
37. Jensen RA, Page DL, Holt JT. Identification of genes expressed in premalignant breast disease by microscopy-directed cloning. Proc Natl Acad Sci USA 1994; 91:9257-9261. (Pubitemid 24297893)
38. Tooker P, Yen WC, Ng SC, et al. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 2007; 67:4425-4433. (Pubitemid 46815092)
39. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in nonsmall cell lung cancer cell lines. Cancer Res 2004; 64:3761-3766. (Pubitemid 38697284)
40. Kwon WS, Rha SY, Choi YH, et al. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 2006; 16:429-438. (Pubitemid 43804800)
41. Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 2007; 120:1355-1363.
42. Rosell R, Vergnenegre A, Liu B, et al. Biomarkers in lung oncology. Pulm Pharmacol Ther 2010. doi: 10.1016/j.pupt.2010.05.003.
43. Bergman AM, Eijk PP, Ruiz van Haperen VW, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65:9510-9516. (Pubitemid 41508021)
44. Zhou J, Oliveira P, Li X, et al. Modulation of the ribonucleotide reductase- antimetabolite drug interaction in cancer cell lines. J Nucleic Acids 2010; 2010:597098.
45. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced nonsmall-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17:1818-1825. (Pubitemid 44884058)
46. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced nonsmall cell lung cancer patients. Clin Cancer Res 2004; 10:1318-1325. (Pubitemid 38365223)
47. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-808. (Pubitemid 46294612)
48. Bepler G, Sommers KE, Cantor A, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable nonsmall cell lung cancer. J Thorac Oncol 2008; 3:1112-1118.
49. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic nonsmall-cell lung cancer. Oncogene 2003; 22:3548-3553. (Pubitemid 36765314)
50. Souglakos J, Boukovinas I, Taron M, et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 2008; 98:1710-1715. (Pubitemid 351684679)
51. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysisdirected individualized therapy in advanced nonsmall-cell lung cancer. J Clin Oncol 2007; 25:2741-2746. (Pubitemid 47123182)
52. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected nonsmall-cell lung cancer. PLoS One 2007; 2:e1129.
53. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13:2443-2449. (Pubitemid 39377848)
54. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13:7413-7420.
55. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63:6221-6228. (Pubitemid 37255167)
56. Rosell R, Cuello M, Cecere F, et al. Usefulness of predictive tests for cancer treatment. Bull Cancer 2006; 93:E101-E108.
57. Stordal B, Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets 2009; 9:354-365.
58. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in nonsmallcell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009; 4:e5133.
59. Kim H, Chen J, Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007; 316:1202-1205. (Pubitemid 46877484)
60. Wang B, Matsuoka S, Ballif BA, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316:1194-1198. (Pubitemid 46877482)
61. Sobhian B, Shao G, Lilli DR, et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007; 316:1198-1202. (Pubitemid 46877483)
62. Yan J, Kim YS, Yang XP, et al. The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res 2007; 67:6647-6656. (Pubitemid 47105510)
63. Aschele C, Debernardis D, Casazza S, et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17:1760-1770. (Pubitemid 29269245)
64. Smorenburg CH, Peters GJ, van Groeningen CJ, et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006; 17:35-42. (Pubitemid 43033837)
65. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 2008; 26:3543-3551.
66. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14:253-263.
67. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440.
68. Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66:431-438. (Pubitemid 36937028)
69. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human nonsmall-cell lung cancer cells. Mol Pharmacol 2005; 68:110-118. (Pubitemid 41002949)
70. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107:1589-1596. (Pubitemid 44546920)
71. Monica V, Scagliotti GV, Ceppi P, et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 2009; 15:7547-7552.
72. Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010; 28:1534-1539.
73. Wu MF, Hsiao YM, Huang CF, et al. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in nonsmall cell lung cancer cells. J Thorac Oncol 2010; 5:1143-1151.
74. Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 2010; 101:161-166.
75. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced nonsmall-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009; 27:3540-3546.
76. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27:2530-2535.
77. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91. (Pubitemid 34438898)